Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961668priorityCriticalpatent/ECSP961668A/en
Publication of ECSP961668ApublicationCriticalpatent/ECSP961668A/en
Esta invención está relacionada a los resultados obtenidos en pesquisa deoxiribonucleasa humana I (IDNasa), un fosfodieserasa que es capaz de hidrolizar ácido polideoxiribonucleico. Se relaciona generalmente a formas modificadas (variantes) de la Dnasa I humana y su preparación por métodos de DNA recombinante, para composiciones farmacéuticas por las cuales su utilidad puede ser explotada clinicamente, y métodos de utilizar estas variantes DNasa I y composiciones de la misma, todo según consta en la memoria descrptiva reivindicaciones y dibujos.This invention is related to the results obtained in the investigation of human deoxyribonuclease I (IDNase), a phosphodierase that is capable of hydrolyzing polideoxyribonucleic acid. It is generally related to modified forms (variants) of human Dnase I and their preparation by recombinant DNA methods, for pharmaceutical compositions for which their utility can be clinically exploited, and methods of using these DNase I variants and compositions thereof, all as stated in the descriptive memory claims and drawings.
ECSP9616681996-02-211996-02-21
DNASA I HUMAN VARIANTS
ECSP961668A
(en)
APPLICATION OF SPHINGOMYELINASE FOR INCREASING THE LEVELS OF CERAMIDES IN THE SKIN AND MICROSCOPIC SHELLS, AND ALSO CONTAINING ITS DERMATOLOGICAL AND COSMETIC COMPOSITIONS THAT ARE RELIABLE FOR LOCAL APPLICATION
"PHARMACEUTICAL COMPOSITION TO INHIBIT SERINPROTEASE ACTIVITY, IN VITRO METHOD TO INHIBIT SERINPROTEASE ACTIVITY AND METHOD TO PREPARE SUCH COMPOSITION".